サンプル依頼リスト カート
  • English
  • Korean
表紙：遺伝子予測ツールの世界市場-2023年～2030年
市場調査レポート
商品コード
1374773

遺伝子予測ツールの世界市場-2023年～2030年

Global Gene Prediction Tool Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
遺伝子予測ツールの世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の遺伝子予測ツール市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって大きな成長と変貌を遂げてきました。基本的に、遺伝子予測はゲノムに沿って遺伝子を特定することを含みます。遺伝子をコードするゲノムDNAの領域を特定するプロセスは、遺伝子探索と呼ばれることもあります。タンパク質をコードする遺伝子、RNA、および調節遺伝子のような他の機能的構成要素もこれに含まれます。

特に新興経済諸国における政府投資や研究開発は、今後も先進的なソフトウェアやサービスの利用を促進し、世界の遺伝子予測ツール市場を押し上げると思われます。それぞれの革新的製品には、JIGSAW、GENEIDのような創薬への新規ツールの使用が含まれます。

市場促進要因：市場抑制要因

共同研究およびイニシアチブの拡大

新興経済諸国は、高額の投資、所得水準、インフラ整備に牽引され、ヘルスケア分野の改善において急速な成長を遂げています。いくつかの国では、研究の高まりにより、遺伝子予測ツールに対する大きな需要が発生しています。各国の技術進歩に伴う様々な製品の発売は、市場の成長を促進する重要な要因であろう。

2022年1月18日、サーモフィッシャーサイエンティフィックとオンコサイトコーポレーションは、Ion Torrent Genexus Systemを用いた体外診断用医薬品（IVD）の共同開発・販売契約を締結しました。精密診断企業であるOncocyte Corporationは、がんの発見、管理、モニタリングにおいて重要な意思決定に役立つ明確な知見を提供することにより、患者の転帰を改善しています。

また、2023年7月20日、臨床段階のゲノム医療企業であるSangamo Therapeutics, Inc.と、単回投与のエピジェネティック編集治療法を発明したゲノム医療企業であるChroma Medicine, Inc.は、配列特異的なDNA認識用のジンクフィンガータンパク質（ZFP）を用いたエピジェネティック医薬品の開発のため、研究評価、オプション、ライセンス契約を締結しました。

さらに、いくつかの疾患の管理に新しい技術やソフトウェアの利用が増加しています。人々の意識の高まりと革新的な診断や治療製品開発のための研究の増加は、遺伝子予測ツール市場の成長を促進する主な要因です。

遺伝子予測ツールに関連する限界

最近のレビューでは、タンパク質をコードする遺伝子を自動ゲノムアノテーション手法で適切に同定することは依然として困難であるという事実が注目されています。大量の遺伝子配列の分岐、真核生物のエクソンマッピングの複雑さ、ドラフトゲノムアセンブリの状態、あるいは古典的な遺伝形質との差異などが、この失敗の要因である可能性があります。

したがって、現在使用されている多くの遺伝子予測アルゴリズムを比較することは、その信頼性を評価し、最も有望な戦術を特定し、タンパク質データベースにおける間違いの伝播を止めるために極めて重要です。

このレポートの詳細- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 共同研究やイニシアチブの拡大
      • 技術的進歩と開発の高まり
    • 抑制要因
      • 遺伝子予測ツールに関連する限界
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 コンポーネント別

  • ソフトウェア
  • サービス
    • メグルミンアンチモニアート（グルカンチム）
    • 類似性に基づく検索
    • Ab-Initio予測

第8章 方法別

  • 類似性に基づく検索
  • Ab-Initio予測

第9章 アプリケーション別

  • 創薬
  • 遺伝子疾患診断
  • 生物医学研究
  • その他

第10章 エンドユーザー別

  • 病院
  • バイオテクノロジー・ライフサイエンス企業
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Thermo Fisher Scientific Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Softberry, Inc.
  • Illumina, Inc.
  • QIAGEN
  • GenScript
  • DNASTAR
  • BGI
  • Geneious
  • Sangamo Therapeutics
  • Takara Bio Inc.

第14章 付録

目次
Product Code: BT7171

Overview

The global gene prediction tool market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Basically, gene prediction involves identifying genes along the genome. The process of locating the areas of genomic DNA which encode genes is sometimes referred to as gene discovery. Genes that code for proteins, RNA, and other functional components like regulatory genes are included in this.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced software or services and boost the global gene prediction tool market. The respective innovative products includes the use of novel tools such as JIGSAW, GENEID for drug discovery.

Market Dynamics: Drivers & Restraints

Growing collaborations and initiatives

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for gene prediction tool owing to the rising research. Various product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On January 18, 2022, Thermo Fisher Scientific and Oncocyte Corporation have entered into a development and collaborative marketing arrangement for a pair distributed in vitro diagnostic (IVD) assessments on the Ion Torrent Genexus System. A precision diagnostics company, Oncocyte Corporation, improving patient outcomes by delivering clear insights that inform crucial decisions in the detection, management, and monitoring of cancer.

Additionally, on July 20, 2023, in order to develop epigenetic drugs using zinc finger proteins (ZFPs) for DNA recognition which is sequence-specific, a clinical-stage genomic medicine company, Sangamo Therapeutics, Inc., and Chroma Medicine, Inc., a genomic medicine company that invented single-dose epigenetic editing treatments, have entered into a research assessment, option, and license agreement.

Furthermore, the rising utilization of novel technology and software for the management of several diseases. Rising awareness among people and increasing research for innovative diagnostic or treatment product development will be a major factor driving the growth of the gene prediction tools market.

Limitations associated with the gene prediction tools

Recent reviews have brought attention to the fact that protein-coding genes are still difficult for automated genome annotation methods to appropriately identify. Significant amounts of genetic sequence divergence, the intricacy of eukaryotic exon mapping, the state of the draft genome assemblies, or variations from classical genetic traits could all be factors in this failure.

Therefore, it is crucial to compare the many gene prediction algorithms now in use in order to gauge their dependability, pinpoint the most promising tactics, as well as to stop the propagation of mistakes in protein databases.

For more details on this report - Request for Sample

Segment Analysis

The global gene prediction tool market is segmented based on component, method, application, end user and region.

Ab-Initio Prediction segment accounted for approximately 59% of market share

In the absence of an experimentally solved structure for a related or homologous protein, a technique known as ab initio prediction of protein structures can be used to ascertain the tertiary structure of a protein. This approach creates protein structure that is influenced by energy function. The difficult endeavor of predicting protein structures solely from sequence data and without the use of templates is known as ab initio prediction.

It is frequently broken down into two independent sub-problems: the method of exploring the conformational space and the scoring system that can discriminate native or native-like structures from non-native ones. A reliable scoring system that can always direct a search towards the native fold doesn't exist yet, and there is no universal search strategy that can provide a sizeable sample of near-natives. Pathway models integrate the search and the scoring function.

According to Briefings in Bioinformatics in 2021, a program called TSSFinder was used to describe the promoter sequences from Eukaryotic species. The initial transcription start site (TSS) prediction approach that uses a probabilistic model based on linear chain conditional random fields (LCCRFs) is TSSFinder, which was originally disclosed in the literature. TSSFinder may be tailored to new organisms and is more accurate than previously released tools.

Geographical Penetration

North America accounted for around 37% of market share in 2022

Due to the rising need for gene prediction tool in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for gene prediction tool.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of tool for research, and increase in biopharmaceutical or bioinformatics business establishment across the region are also contributing to the growth of gene prediction tool market share of this region. The market in this area is growing as people become more aware of various novel innovative tools. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global gene prediction tool market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for gene prediction tool in the U.S. United States have been proactive in executing several initiatives or researches, stimulating gene prediction tool demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene prediction tool market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for gene prediction tool. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global gene prediction tool market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for iinovative tools, like ab-initio prediction tools.

Key Developments

  • On June 1, 2023, the new PrimateAI-3D artificial intelligence (AI) algorithm, developed by Illumina Inc., an innovator in DNA sequencing as well as array-based technologies, predicts disease-causing genetic variants in patients with unparalleled accuracy. Two papers outlining the development of the algorithm and its implementation to fifty thousand genomes in the United Kingdom Biobank cohort were published in Science on June 2 (issue 6648) with the results.
  • On January 23, 2023, By incorporating game-changing evaluation speed to assess and comprehend whole exome sequencing (WES), whole genome sequencing (WGS), and large panel sequencing data, the bioinformatics division of QIAGEN, QIAGEN Digital Insights, improved QIAGEN CLC Genomics Workbench Premium, which removes the data-analysis obstacles of next-generation sequencing (NGS).
  • On May 16, 2022, A no-cost program for the annotation, characterisation, and visualization of specific antibodies will be made available by Geneious Biologics. The Geneious Biologics antibody annotation's potency can be personally experienced by researchers thanks to the online free antibody sequence analysis tool.

Competitive Landscape

The major global players in the market include: Thermo Fisher Scientific Inc., Softberry, Inc., Illumina, Inc., QIAGEN, GenScript, DNASTAR, BGI,Geneious, Sangamo Therapeutics and Takara Bio Inc..

Why Purchase the Report?

  • To visualize the global gene prediction tool market segmentation based on component, method, application, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of gene prediction tool market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global gene prediction tool market report would provide approximately 69 tables, 66 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Component
  • 3.2. Snippet by Method
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing collaborations and initiatives
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Limitations associated with the gene prediction tools
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 7.1.2. Market Attractiveness Index, By Component
  • 7.2. Software*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Services
    • 7.3.1. Meglumine Antimoniate (Glucantim)
    • 7.3.2. Similarity Based Searches
    • 7.3.3. Ab-Initio Prediction

8. By Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 8.1.2. Market Attractiveness Index, By Method
  • 8.2. Similarity Based Searches*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ab-Initio Prediction

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Drug Discovery *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Genetic Disorder Diagnosis
  • 9.4. Biomedical Research
  • 9.5. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Biotechnology and Life Science Companies
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Softberry, Inc.
  • 13.3. Illumina, Inc.
  • 13.4. QIAGEN
  • 13.5. GenScript
  • 13.6. DNASTAR
  • 13.7. BGI
  • 13.8. Geneious
  • 13.9. Sangamo Therapeutics
  • 13.10. Takara Bio Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us